Galantamine
Galantamine.JPG

Galantamine

CLINICAL USE

Mild to moderate dementia in Alzheimer’s disease

DOSE IN NORMAL RENAL FUNCTION

4–12 mg twice daily

PHARMACOKINETICS

  • Molecular weight                           :368.3 (as hydrobromide)
  • %Protein binding                           :18
  • %Excreted unchanged in urine     : 18–22
  • Volume of distribution (L/kg)       :175 litres
  • half-life – normal/ESRD (hrs)      :7–8 (XL: 8–10)/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function but start with lower doses

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Dialysed. Dose as in GFR
  • <10           : mL/min
  • HD                     :Dialysed. Dose as in GFR
  • <10           : mL/min
  • HDF/high flux   :Dialysed. Dose as in GFR
  • <10           : mL/min
  • CAV/VVHD      :Dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Antibacterials: erythromycin increases plasma concentration of galantamine

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments





    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs